These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458 [TBL] [Abstract][Full Text] [Related]
24. Resistance to fluoroquinolones by the combination of target site mutations and enhanced expression of genes for efflux pumps in Shigella flexneri and Shigella sonnei strains isolated in Korea. Kim JY; Kim SH; Jeon SM; Park MS; Rhie HG; Lee BK Clin Microbiol Infect; 2008 Aug; 14(8):760-5. PubMed ID: 18727800 [TBL] [Abstract][Full Text] [Related]
25. Fluoroquinolone resistance and molecular characterization of gyrA and parC quinolone resistance-determining regions in Escherichia coli isolated from poultry. Vanni M; Meucci V; Tognetti R; Cagnardi P; Montesissa C; Piccirillo A; Rossi AM; Di Bello D; Intorre L Poult Sci; 2014 Apr; 93(4):856-63. PubMed ID: 24706962 [TBL] [Abstract][Full Text] [Related]
26. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy. Montanari MP; Tili E; Cochetti I; Mingoia M; Manzin A; Varaldo PE Microb Drug Resist; 2004; 10(3):209-17. PubMed ID: 15383164 [TBL] [Abstract][Full Text] [Related]
27. gyrA and parC mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa from Nini Hospital in north Lebanon. Salma R; Dabboussi F; Kassaa I; Khudary R; Hamze M J Infect Chemother; 2013 Feb; 19(1):77-81. PubMed ID: 22821356 [TBL] [Abstract][Full Text] [Related]
28. Characterization of fluoroquinolone-resistant Shigella flexneri in Hangzhou area of China. Pu XY; Pan JC; Wang HQ; Zhang W; Huang ZC; Gu YM J Antimicrob Chemother; 2009 May; 63(5):917-20. PubMed ID: 19297378 [TBL] [Abstract][Full Text] [Related]
29. Mutations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in clinical strains of fluoroquinolone-resistant Shigella in Anhui, China. Hu LF; Li JB; Ye Y; Li X J Microbiol; 2007 Apr; 45(2):168-70. PubMed ID: 17483803 [TBL] [Abstract][Full Text] [Related]
30. Winter kill in intensively stocked channel catfish (Ictalurus punctatus): Coinfection with Aeromonas veronii, Streptococcus parauberis and Shewanella putrefaciens. Mohammed HH; Peatman E J Fish Dis; 2018 Sep; 41(9):1339-1347. PubMed ID: 29882217 [TBL] [Abstract][Full Text] [Related]
31. Prevalence of gyrA Mutations in Nalidixic Acid-Resistant Strains of Salmonella Enteritidis Isolated from Humans, Food, Chickens, and the Farm Environment in Brazil. Campioni F; Souza RA; Martins VV; Stehling EG; Bergamini AMM; Falcão JP Microb Drug Resist; 2017 Jun; 23(4):421-428. PubMed ID: 27559761 [TBL] [Abstract][Full Text] [Related]
32. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003. Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779 [TBL] [Abstract][Full Text] [Related]
33. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Rafii F; Park M; Novak JS Antimicrob Agents Chemother; 2005 Feb; 49(2):488-92. PubMed ID: 15673722 [TBL] [Abstract][Full Text] [Related]
34. Substitutions of Ser83Leu in GyrA and Ser80Leu in ParC Associated with Quinolone Resistance in Acinetobacter pittii. Gu DX; Hu YJ; Zhou HW; Zhang R; Chen GX Microb Drug Resist; 2015 Jun; 21(3):345-51. PubMed ID: 25514581 [TBL] [Abstract][Full Text] [Related]
35. Resistance to fluoroquinolones linked to gyrA and par C mutations and overexpression of acr AB efflux pump in Salmonella enterica serotype Choleraesuis. Chu C; Su LH; Chu CH; Baucheron S; Cloeckaert A; Chiu CH Microb Drug Resist; 2005; 11(3):248-53. PubMed ID: 16201927 [TBL] [Abstract][Full Text] [Related]
37. Mutant prevention concentrations of levofloxacin, pazufloxacin and ciprofloxacin for A. baumannii and mutations in gyrA and parC genes. Sun C; Hao J; Dou M; Gong Y J Antibiot (Tokyo); 2015 May; 68(5):313-7. PubMed ID: 25351948 [TBL] [Abstract][Full Text] [Related]
38. Investigation of fluoroquinolone resistance mechanism in Mycoplasma hominis isolated from urogenital samples in a Chinese hospital. Zhang H; Zheng L; Zhao J; Ding S; Xia Y J Med Microbiol; 2019 Feb; 68(2):206-210. PubMed ID: 30632961 [TBL] [Abstract][Full Text] [Related]
39. [Mutations of gyrA gene and parC gene in fluoroquinolone-resistant Escherichia coli isolates from sporadic diarrheal cases]. Ishiguro F; Toho M; Yamazaki M; Matsuyuki S; Moriya K; Tanaka D; Isobe J; Kyota Y; Muraoka M Kansenshogaku Zasshi; 2006 Sep; 80(5):507-12. PubMed ID: 17073264 [TBL] [Abstract][Full Text] [Related]
40. The molecular mechanisms of fluoroquinolone resistance found in rectal swab isolates of Enterobacterales from men undergoing a transrectal prostate biopsy: the rationale for targeted prophylaxis. Piekarska K; Zacharczuk K; Wołkowicz T; Mokrzyś M; Wolaniuk N; Nowakowska M; Szempliński S; Dobruch J; Gierczyński R Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):81. PubMed ID: 34876123 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]